

Amendments to the Claims:

The listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

1. (cancelled)
2. (Withdrawn) A pharmaceutical composition method for preventing cyclosporin A-induced cytotoxicity by the overexpression of cyclophilin with PPIase activity in transplanted cells, comprising using a cell for use in transplantation in which the cyclophilin protein with peptidyl-prolyl-cis-trans isomerase activity is overexpressed comprising a recombinant expression vector which can express the cyclophilin protein in such a sufficient amount as to in an amount sufficient to reduce the toxicity induced by cyclosporin A or its analogues in transplanted cells.
3. (Withdrawn) The method The pharmaceutical composition as defined in claim 2, wherein the cell for use in transplantation transplanted cells are myoblasts is a myoblast.
4. (cancelled).
5. (cancelled).
6. (Withdrawn) A method of preparing cells for use in the transplantation which are resistant to cyclosporin A or its analogues, The method of claim 2 wherein the cell for use in the transplantation is prepared by a process comprising the steps of introducing a gene encoding a cyclophilin protein with PPIase peptidyl-prolyl-cis-trans isomerase activity into a vector to construct a recombinant expression vector, transfecting the recombinant expression vector into cells to be transplanted, culturing the transfected cells, and selecting cells in which the cyclophilin with PPIase peptidyl-prolyl-cis-trans isomerase activity is over-expressed.
7. (Withdrawn) A method of preparing cells for use in the transplantation which are resistant to cyclosporin A or its analogues, The method of claim 6, wherein the step of culturing the transformed cell is performed comprising the steps of culturing cells to be transplanted in the presence of cyclosporin A or its analogues and recovering viable cells from the cultures.
8. (Withdrawn) The method as defined in claim [16] 7, wherein the cells are myoblasts step of selecting a cell in which the cyclophilin with peptidyl-prolyl-cis-trans isomerase activity is overexpressed is performed by recovering a viable cell from the culture.

9. (cancelled).
10. (New) A pharmaceutical composition for preventing cyclosporin A-induced cytotoxicity by the overexpression of cyclophilin with PPIase activity in a transplanted cell, wherein the transplanted cell is an H0c2 rat cardiac myoblast transfected with a vector expressing a CypA gene.
11. (New) The pharmaceutical composition of claim 10, wherein the CypA gene is mutated so as to express a CypA protein comprising a phenylalanine residue instead of a tryptophan residue at position 121.
12. (New) The pharmaceutical composition of claim 10 wherein the cell is designated as CypA/wt or CypA/W121F.
13. (New) A method of preparing a cell for use in transplantation that is resistant to cyclosporin A or its analogues, comprising the steps of introducing a gene encoding a cyclophilin protein with PPIase activity into a vector to construct a recombinant expression vector, transfecting the recombinant expression vector into an H0c2 rat cardiac myoblast, culturing the transfected H0c2 rat cardiac myoblast, and selecting a cultured H0c2 rat cardiac myoblast in which the cyclophilin with PPIase activity is over-expressed.
14. (New) The method of claim 13 wherein the CypA gene is mutated so as to express a CypA protein comprising a phenylalanine residue instead of a tryptophan residue at position 121.
15. (New) The method of claim 13 wherein the cell is designated as CypA/wt or CypA/W121F.